ADVFN - Advanced Financial Network.
HOME» NASDAQ » F » FACT Stock Price » FACT Stock News

Facet Biotech Share News

 Facet Biotech (mm) Stock Price
FACT Stock Price
 Facet Biotech (mm) Stock Chart
FACT Stock Chart
 Facet Biotech (mm) Stock News
FACT Stock News
 Facet Biotech (mm) Company Information
FACT Company Information
 Facet Biotech (mm) Stock Trades
FACT Stock Trades

Facet Allows Two Biggest Shareholders To Raise Stakes

DOW JONES NEWSWIRES Facet Biotech Corp. (FACT) is allowing its two biggest shareholders to increase their stakes without triggering a "poison pill" provision, amid its efforts to ward off Biogen Idec's (BIIB) $420 million acquisition bid. Facet President and Chief Executive Faheem Hasnain said, "We are pleased that our two largest stockholders, who collectively own 28.7% of shares outstanding, have informed us that they do not intend to tender their shares into Biogen Idec's offer and that they want greater flexibility to acquire additional shares of the company." Facet shares were recently down 3.5% at $16.16, while Biogen gained 1.5% to $50.16. There is a 12 a.m. EST Thursday deadline for Facet holders to tender their shares in support of Biogen's $17.50 a share offer. If a majority doesn't, Biogen said it will walk away. Hasnain reiterated Wednesday that Biogen's boosted offer is inadequate and undervalues the company, adding that Facet is open to opportunities that would provide full and fair value for our stockholders." It again stated its offer to engage in due diligence talks with Biogen Idec, along with third parties. The cash-rich California-based drug developer and Biogen have worked together since 2005 on treatments for multiple sclerosis and solid tumors. Facet contends that Biogen is trying to cheaply acquire the full rights to daclizumab, a multiple-sclerosis treatment in development by the companies. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com;

Stock News for Facet Biotech (FACT)
DateTimeHeadline
03/09/201017:47:33Abbott To Buy Facet Biotech For $722 Million, Adding To Pipeline
12/17/200910:29:13Facet Biotech Shareholders Reject Biogen Idec Offer
12/16/200913:36:15Facet Allows Two Biggest Shareholders To Raise Stakes
12/15/200914:33:26Biogen May Run Proxy Fight If Most Of Facet Holders Back Deal
12/11/200913:03:07Biogen Idec Reiterates Facet Bid Is 'Best And Final Offer'
12/10/200909:36:12Facet Board Rejects Biogen Idec's Boosted Takevoer Bid
10/20/200908:25:04Biogen Idec 3Q Net Up 34%; Cautious Revenue View Given

Facet Biotech and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad